Repligen Corp (RGEN) Stock Price, Quote & News

Company Profile

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sampl...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 781 250 0111

Fax: 781 250 0115

Website: www.repligen.com

Address:

Building 1, Suite 100 41 Seyon Street, Waltham, United States

Tfizzle Mar. 8 at 4:08 PM

$RGEN 134 this week

0 · Reply

Tfizzle Mar. 6 at 8:52 PM

$USO $DJT $QQQ why do I get the feeling with Oil rsi over 80 and overbought that somehow Trump hits pause on WAR over the weekend in full TACO mode? $WHR $RGEN

1 · Reply

Tfizzle Mar. 5 at 10:52 PM

$RGEN multiple bottom today. Temporary bottom is in. 130’s next week

0 · Reply

BillionerOfKing Mar. 4 at 9:20 PM

$RGEN Current Stock Price: $125.83 Contracts to trade: $125.0 RGEN Mar 20 2026 Call Entry: $6.20 Exit: $12.26 ROI: 98% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 26 at 5:39 PM

$RGEN Share Price: $131.48 Contract Selected: Aug 21, 2026 $130 Calls Buy Zone: $14.96 – $18.48 Target Zone: $24.73 – $30.22 Potential Upside: 56% ROI Time to Expiration: 175 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Feb. 26 at 12:04 AM

$RGEN RSI: 29.95, MACD: -6.7014 Vol: 7.96, MA20: 141.94, MA50: 155.44 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Feb. 25 at 3:42 PM

$RGEN just delivered the kind of quarter bulls wait for. Q4 EPS topped estimates, and revenues surged 18% Y/Y — driven by solid organic growth and stronger margins heading into 2026. That’s not just a beat… that’s momentum building. 🚀 Discover what’s fueling the growth story here 👉 https://www.zacks.com/stock/news/2874936/repligens-q4-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2874936-teaser-35074&ADID=SYND_STOCKTWITS_TWEET_2_2874936_TEASER_35074

0 · Reply

ZacksResearch Feb. 25 at 2:42 PM

$RGEN beats earnings, but lagging the industry rally — is it time to hold? 📊 The company reported Q4 EPS of 49 cents, topping estimates with an 18% year-over-year revenue increase. However, shares have only risen 11% in the past six months compared to the industry's 23.3% rally. Discover the full breakdown here 👉 https://www.zacks.com/stock/news/2874936/repligens-q4-earnings-beat-estimates-revenues-surge-yy?cid=sm-stocktwits-2-2874936-body-35071&ADID=SYND_STOCKTWITS_TWEET_2_2874936_BODY_35071

0 · Reply

StocktwitsEarnings Feb. 24 at 12:39 PM

$RGEN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.24 up 140.00% YoY • Reported revenue of $197.91M up 18.12% YoY • Repligen expects full year 2026 revenue of $810M to $840M, representing 10% to 14% reported growth and 9% to 13% organic growth, alongside 150 bps adjusted operating margin expansion.

0 · Reply

TSFStocks Feb. 18 at 8:19 PM

$RGEN

0 · Reply

Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 3, 2026, 10:36 AM EST - 12 days ago

Baron Health Care Fund Q4 2025 Recent Activity

ACLX ARQT BSX ELAN MASI SYK TMO

Feb 24, 2026, 2:28 PM EST - 19 days ago

Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 7:30 AM EST - 19 days ago

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 15, 2026, 6:08 PM EST - 27 days ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ABT ALKT CDNA CWAN DKNG DT ESTA

Feb 10, 2026, 7:30 AM EST - 4 weeks ago

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Jan 25, 2026, 10:09 AM EST - 7 weeks ago

Conestoga Mid Cap Composite Q4 2025 Leaders And Laggards

BSY CSGP GNRC IDXX JKHY POOL ROL

Jan 14, 2026, 2:55 AM EST - 2 months ago

Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 7:30 AM EST - 2 months ago

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Dec 18, 2025, 7:30 AM EST - 3 months ago

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

Dec 16, 2025, 7:30 AM EST - 3 months ago

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

Dec 3, 2025, 4:43 PM EST - 3 months ago

Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 26, 2025, 7:30 AM EST - 3 months ago

Repligen Corporation to Present at Evercore Healthcare Conference

Nov 18, 2025, 2:48 PM EST - 4 months ago

Repligen Corporation (RGEN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Nov 18, 2025, 11:18 AM EST - 4 months ago

Repligen Corporation (RGEN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 14, 2025, 3:28 AM EST - 4 months ago

Repligen: Rare Growth In The Biopharma Supplies Industry

Nov 11, 2025, 3:11 PM EST - 4 months ago

Repligen Corporation (RGEN) Presents at Stifel 2025 Healthcare Conference Transcript

Nov 10, 2025, 1:41 PM EST - 4 months ago

Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Oct 28, 2025, 5:01 PM EDT - 4 months ago

Repligen Corporation (RGEN) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 7:30 AM EDT - 4 months ago

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Oct 15, 2025, 7:30 AM EDT - 5 months ago

Repligen to Report Third Quarter 2025 Financial Results

Sep 25, 2025, 11:37 AM EDT - 6 months ago

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 4, 2025, 10:32 AM EDT - 6 months ago

Repligen Corporation (RGEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 28, 2025, 6:20 AM EDT - 7 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY BNTX DHR GRAL ILMN IONS MRNA

Aug 22, 2025, 7:30 AM EDT - 7 months ago

Repligen Corporation to Present at Upcoming September Conferences

Aug 14, 2025, 3:24 PM EDT - 7 months ago

Repligen Corporation: Still Navigating Through The Covid Cliff

Jul 31, 2025, 10:45 AM EDT - 8 months ago

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Jul 31, 2025, 7:30 AM EDT - 8 months ago

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

Jul 29, 2025, 5:31 PM EDT - 8 months ago

Repligen Corporation (RGEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:30 AM EDT - 8 months ago

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

Jul 17, 2025, 7:30 AM EDT - 8 months ago

Repligen to Report Second Quarter 2025 Financial Results

Jun 16, 2025, 8:00 AM EDT - 9 months ago

908 Devices Appoints Christopher D. Brown to its Board of Directors

MASS

May 27, 2025, 7:30 AM EDT - 10 months ago

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 7, 2025, 7:30 AM EDT - 11 months ago

Repligen Corporation to Present at Upcoming May Investor Conferences

Apr 29, 2025, 12:58 PM EDT - 11 months ago

Repligen Corporation (RGEN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 7:30 AM EDT - 11 months ago

Repligen Reports First Quarter 2025 Financial Results

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Mar 20, 2025, 7:52 AM EDT - 1 year ago

Repligen: Ongoing Bioprocessing Market Recovery

Mar 4, 2025, 1:26 PM EST - 1 year ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MASS

Mar 4, 2025, 7:30 AM EST - 1 year ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

MASS

Feb 20, 2025, 2:53 PM EST - 1 year ago

Repligen Corporation (RGEN) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:00 PM EST - 1 year ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Feb 11, 2025, 7:30 AM EST - 1 year ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Jan 7, 2025, 7:30 AM EST - 1 year ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:30 AM EST - 1 year ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Dec 16, 2024, 8:11 AM EST - 1 year ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

BLFS

Dec 12, 2024, 7:30 AM EST - 1 year ago

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Dec 9, 2024, 7:30 AM EST - 1 year ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Nov 12, 2024, 3:07 PM EST - 1 year ago

Repligen Corporation (RGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:19 PM EST - 1 year ago

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

Tfizzle Mar. 8 at 4:08 PM

$RGEN 134 this week

0 · Reply

Tfizzle Mar. 6 at 8:52 PM

$USO $DJT $QQQ why do I get the feeling with Oil rsi over 80 and overbought that somehow Trump hits pause on WAR over the weekend in full TACO mode? $WHR $RGEN

1 · Reply

Tfizzle Mar. 5 at 10:52 PM

$RGEN multiple bottom today. Temporary bottom is in. 130’s next week

0 · Reply

BillionerOfKing Mar. 4 at 9:20 PM

0 · Reply

SuperGreenToday Feb. 26 at 5:39 PM

0 · Reply

OfficialStocktwitsUser Feb. 26 at 12:04 AM

0 · Reply

ZacksResearch Feb. 25 at 3:42 PM

0 · Reply

ZacksResearch Feb. 25 at 2:42 PM

0 · Reply

StocktwitsEarnings Feb. 24 at 12:39 PM

0 · Reply

TSFStocks Feb. 18 at 8:19 PM

$RGEN

0 · Reply

SuperGreenToday Feb. 9 at 8:08 PM

$RGEN Share Price: $142.49 Contract Selected: Jun 18, 2026 $140 Calls Buy Zone: $13.86 – $17.12 Target Zone: $24.01 – $29.34 Potential Upside: 64% ROI Time to Expiration: 128 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

AlgorithmicAdvisors Feb. 4 at 11:49 AM

$RGEN is a life sciences tools company with a dominant position in cell culture; growth is solid but decelerating as biopharma capex softens.

0 · Reply

Estimize Feb. 4 at 11:01 AM

Wall St is expecting 0.45 EPS for $RGEN Q1 [Reporting 05/05 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

SuperGreenToday Jan. 29 at 4:44 PM

$RGEN Share Price: $154.66 Contract Selected: Jun 18, 2026 $155 Calls Buy Zone: $13.94 – $17.22 Target Zone: $22.98 – $28.08 Potential Upside: 56% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Estimize Jan. 19 at 12:03 PM

Wall St is expecting 0.44 EPS for $RGEN Q4 [Reporting 02/25 BMO] http://www.estimize.com/intro/rgen?chart=historical&metric_name=eps&utm_co

0 · Reply

OfficialStocktwitsUser Jan. 6 at 4:28 PM

$RGEN RSI: 72.29, MACD: 2.5962 Vol: 4.18, MA20: 163.33, MA50: 159.25 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

KaleKing Dec. 25 at 9:35 AM

$RGEN Risk premia compress only when proof accumulates, because growth without leverage now attracts skepticism. A coherent operating roadmap would be catalytic.

0 · Reply

OfficialStocktwitsUser Dec. 25 at 8:53 AM

$RGEN RSI: 49.84, MACD: 1.8184 Vol: 4.18, MA20: 163.42, MA50: 157.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ortega1963 Dec. 22 at 4:11 PM

$RGEN

0 · Reply

ortega1963 Dec. 22 at 4:07 PM

$RGEN long 166

0 · Reply

JarvisFlow Dec. 15 at 9:07 PM

Barclays has updated their rating for Repligen ( $RGEN ) to Overweight with a price target of 200.

0 · Reply

Market Cap	6.43B
Revenue (ttm)	738.26M
Net Income (ttm)	48.89M
EPS (ttm)	N/A
PE Ratio	66.78
Forward PE	57.87
Profit Margin	6.62%
Debt to Equity Ratio	0.00

Volume	1,115,200
Avg Vol	803,854
Day's Range	N/A - N/A
Shares Out	56.33M
Stochastic %K	10%
Beta	1.14
Analysts	Strong Sell
Price Target	$185.76